
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a promising biopharmaceutical company with a strong commercial presence and a promising drug candidate, VTAMA, in the plaque psoriasis market. Despite a decline in 4Q26 revenue and an increase in non-GAAP expenses, the company has a solid financial position with a cash runway into profitability. The company's diversified pipeline, particularly with its anti-FcRn franchise, provides multiple potential growth opportunities and mitigates potential risks.
Bears say
Roivant Sciences is facing strong competition in the biopharmaceutical industry and their current drug candidate, VTAMA, has limited potential with only one indication for treatment. Furthermore, the company's strategy of incubating discovery-stage companies and health technology startups may not be sustainable in the long term. With a lack of diversity in their drug pipeline and the potential for increased regulation risks, Roivant Sciences has a high-risk profile and is not a strong investment opportunity.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares